Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2017.12.622
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2018
Authors
Publisher
Elsevier BV